Can atogepant (Qulipta) and rimegepant (Nurtec ODT) be taken together?

Can Qulipta and Nurtec Be Taken Together?

Yes, atogepant (Qulipta) and rimegepant (Nurtec ODT) can be taken together based on FDA drug interaction data and emerging clinical evidence, though this represents off-label use requiring careful consideration of the clinical scenario.

Key Evidence Supporting Concurrent Use

FDA Drug Interaction Data

The FDA label for Qulipta explicitly states that co-administration with ubrogepant (another gepant) did not result in significant pharmacokinetic interactions 1. While this specific study evaluated ubrogepant rather than rimegepant, the pharmacological similarity between gepants suggests comparable safety profiles when used together.

Clinical Context for Combination Use

Two distinct clinical scenarios exist:

1. Acute + Preventive Combination (Most Common)

   • Using rimegepant for acute migraine attacks while taking atogepant daily for prevention
   • This is mechanistically sound and supported by drug interaction studies 2
   • No clinically meaningful pharmacokinetic interactions expected

2. Dual Preventive Therapy (Emerging Evidence)

   • Using both atogepant and rimegepant as preventive agents simultaneously
   • A 2026 retrospective study of 37 patients with chronic migraine found this approach significantly reduced headache days (median reduction of 0 days, IQR -5 to 0; p=0.031) and severe migraine days (median reduction of -2 days; p<0.001) 3
   • 22% of patients achieved ≥50% reduction in headache days
   • No significant increase in adverse events (p=0.219) 3

Safety Considerations

Adverse Event Profile

When combining CGRP antagonists, monitor for:

• Gastrointestinal effects: Nausea and constipation are the most common side effects (occurring in 6-9% with atogepant 60mg) 1
• Cardiovascular concerns: One case of ischemic stroke was reported in the dual therapy study, though the patient had multiple pre-existing risk factors 3
• No hepatotoxicity signals have emerged with gepant combinations 1

Critical Caveat

Half of patients (51%) in the dual preventive therapy study discontinued at least one CGRP antagonist, primarily due to insurance restrictions or lack of perceived benefit—not side effects 3. This highlights that while safe, the combination may not provide additional benefit for all patients.

Practical Algorithm for Decision-Making

For Acute + Preventive Use:

• ✓ Safe to use rimegepant for acute attacks while on daily atogepant
• No dose adjustments needed
• Standard monitoring for individual drug side effects

For Dual Preventive Therapy:

1. Consider only after failure of:
   • Single CGRP antagonist (gepant or monoclonal antibody)
   • Other standard preventive medications 4
2. Obtain insurance pre-authorization (major barrier)
3. Trial for minimum 3 months before assessing efficacy 3
4. Monitor cardiovascular risk factors closely, especially in patients with pre-existing vascular disease
5. Discontinue if no meaningful benefit after 3-6 months

Medication Overuse Headache Risk

Important reassurance: Preclinical and preliminary clinical evidence indicates gepants have a low likelihood of inducing medication-overuse headache 5, making them safer than triptans for frequent use (which have a threshold of ≥10 days/month) 6.

Cost and Access Barriers

Both medications are expensive:

• Atogepant: Not specifically priced in evidence but classified as costly
• Rimegepant: Annualized wholesale acquisition cost ranges from $4,959-$5,994 6
• Insurance often restricts dual CGRP therapy, requiring documented failure of other treatments

Bottom Line

The combination is pharmacologically safe with no significant drug-drug interactions, but clinical benefit of dual preventive therapy remains uncertain and should be reserved for refractory chronic migraine cases after exhausting other options. For acute-on-preventive use, this is a reasonable and well-supported strategy 1, 2.